A 31-year-old man with no prior psychiatric history developed a full manic episode after three months of escalating high-dose CBD vaping, with symptoms resolving after discontinuation and treatment with mood stabilizers.
Psychiatrists, emergency medicine physicians, CBD product users, pharmacovigilance researchers
Mania in a patient with zero psychiatric history after high-dose CBD
What the researchers found
A 31-year-old male with no psychiatric history developed irritability, decreased need for sleep, hyperactivity, and aggression after three months of escalating daily CBD use via vaping, reaching high doses before admission. Toxicology screening was negative for other substances. Clinical improvement occurred with mood stabilizers and antipsychotics following CBD discontinuation.
Why it matters
CBD is widely perceived as safe and non-psychoactive, but this case suggests that high-dose CBD may trigger mania in susceptible individuals. The absence of prior psychiatric history and negative toxicology for other substances strengthens the association, though commercial CBD product variability (contamination, mislabeling) complicates interpretation.
The numbers in context
31-year-old male; no prior psychiatric history; 3 months of escalating CBD vaping; negative toxicology for other substances; improved with mood stabilizers and antipsychotics after CBD discontinuation
How the study worked
Single case report documenting the clinical presentation, substance use history, toxicology screening, treatment, and clinical course of a CBD-associated manic episode.
What this study cannot tell us
Single case report cannot establish causation. Commercial CBD products may contain contaminants, other cannabinoids, or be mislabeled. Dose escalation pattern suggests possible dependence behavior. Cannot rule out undiagnosed bipolar disorder that was unmasked rather than caused by CBD. No genetic or family psychiatric history details provided.
How to read the evidence
Single case report with clean toxicology and no psychiatric history provides a notable safety signal, but cannot establish causation or rule out product contamination.
When this study was published
2025 publication
The bigger picture
As CBD products proliferate with minimal regulation, the assumption of complete safety is being challenged by case reports like this. While CBD at therapeutic doses appears generally well-tolerated, high-dose use without medical supervision may carry psychiatric risks, particularly given the variability in commercial product composition.
Questions still open
- Is there a dose threshold above which CBD carries psychiatric risk? Would verified pharmaceutical-grade CBD produce the same effect, or does this reflect product contamination?
Common questions
Can CBD cause mania?
Is CBD safe to use?
Read the original research
Cannabidiol Induced Manic Episode: A Case Report.
Psychopharmacology bulletin, 55(4), 116-122
Citation
Auf, Anas Ibn; Almakki, Razan A; Alhummayani, Nora M. (2025). Cannabidiol Induced Manic Episode: A Case Report.. Psychopharmacology bulletin, 55(4), 116-122. https://doi.org/10.64719/pb.4542
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk